Does MS grey matter pathology progress faster in regions with more damage in connected white matter?

Recruiting

• Conditions: multiple sclerosis; grey matter atrophy; white matter damage

• Registration Number: NL-OMON23313
• Lead Sponsor: VU University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 55

Inclusion Criteria

Patient group:

1. Minimum age 18 years

Exclusion Criteria

1. Past or current clinically relevant non-MS neurological or psychiatric disorder(s)

2. Past or current clinically relevant (auto)immune disorder(s)

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Three measures for WM damage will be assessed, i.e. lesion volume, lesion fractional anisotropy (FA) and NAWM FA, from which a composite WM damage score will be computed. High versus low WM damage scores will then be compared to the atrophy rates in the GM, based on subcortical volume and cortical thickness measures. From this, we can compare atrophy rates of each GM structure from baseline to year 1 between the group of patients with higher damage in the WM tracts connected to that GM structure on the one hand, and the group of patients with lower damage in those WM tracts on the other.<br /><br>Similar calculations will be performed between year 1 and year 2 in order to determine whether a larger increase of WM damage over the first study year is predictive of faster subsequent GM atrophy in the second year.

Secondary Outcome Measures

Name	Time	Method
ext to the measures for GM and WM damage, resting state functional connectivity measurements will be used to assess whether GM and WM damage patterns effect the functional organization of the brain at rest, either prior to GM/WM damage, or following the damage patterns observed.<br>Furthermore, clinical parameters (see section 8.3) will be taken into account, in order to link the structural data to functionality of the brain in the RRMS patients.